Trials / Completed
CompletedNCT06890416
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
A PHASE 3, MULTICENTER, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS ≥50 YEARS OF AGE
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 526 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE | Intramuscular injection |
| BIOLOGICAL | HZ/su VACCINE | intramuscular injection |
Timeline
- Start date
- 2025-04-04
- Primary completion
- 2025-09-30
- Completion
- 2025-09-30
- First posted
- 2025-03-24
- Last updated
- 2025-11-06
Locations
26 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06890416. Inclusion in this directory is not an endorsement.